Full Name
Dr. Neal S. Young MD
Job Title
Hematology Branch, NHLBI/NIH
Company/Affiliation
National Cancer Institute
Speaker Bio
Neal Young is the Chief of the Hematology Branch of the NHLBI. He has worked at NIH for over 50 years and is one of the institution’s most recognized scientists. He is well known for his basic research in a variety of fields and in protocol-driven Clinical Center studies, as well as a clinician caring for his extremely ill patients. Essentially, his fundamental interest has been the pathophysiology of disease and treatments based on the discovery of novel pathogenic mechanisms. His accomplishments display striking scientific originality and have had great practical importance to patients with serious blood diseases.
Dr. Young has led a broad research program at NIH: basic science experimentation in cell biology, immunology, and virology; direct clinical care and interventional research protocols; genetics and genomics; and population-based epidemiology. Some of his seminal contributions include establishing an immune pathophysiology for aplastic anemia; development of highly effective immunosuppressive regimens; drug approvals based on NIH studies for eltrombopag, anti-thymocyte globulin, and eculizumab; fundamental studies of parvovirus B19, including laboratory assays, a candidate vaccine, and discovery of the cellular receptor and genetic resistance; telomere biology disorders in adults, and the first description of TERT gene mutations in humans; pioneering application of single-cell technologies, RNA and DNA, to characterize hematologic diseases (aplastic anemia, large granular lymphocytosis, DADA2, GATA2, and malignant aneuploidy); and characterization of somatic mutation “benign” diseases. He has published almost 600 research articles, including more than two dozen papers in the New England Journal of Medicine, as well as many textbook chapters and monographs; per Google Scholar, his work has been cited more than 85,000 times, and his h-index is 157.
Dr. Young has been elected to the American Society for Clinical Investigation and the American Association of Physicians and is a Master of the American College of Physicians. He has been honored by the American Society of Hematology, ACP, many national hematology societies, and both the American and Vietnamese governments. In the 1990s, Dr. Young established a formal teaching program in Vietnam, which sponsored annual visits of American experts to that country and training of Vietnamese physicians at NIH and elsewhere in the United States. He has been a plenary lecturer at dozens of national congresses.
Dr. Young is renowned as a mentor; comments from trainees frequently cite their experiences as “transformative.” His students now head their own departments in the United States, Europe, Asia, and South America. He has been an American Society of Hematology Global Mentor for trainees from Brazil, Myanmar, India, and the Netherlands. He co-founded and led for a decade the innovative and successful trans-NIH Center for Human Immunology.
Dr. Young has extensive experience as an editor and reviewer, as well as an author. His economic analysis of the Winner’s Curse in PLoS Medicine has been influential in the current crisis in medical publishing. As a Visiting Fellow at New College, Oxford, his collaboration with a philosopher has resulted in a novel and profound language perspective on scientific communication.
Dr. Young has led a broad research program at NIH: basic science experimentation in cell biology, immunology, and virology; direct clinical care and interventional research protocols; genetics and genomics; and population-based epidemiology. Some of his seminal contributions include establishing an immune pathophysiology for aplastic anemia; development of highly effective immunosuppressive regimens; drug approvals based on NIH studies for eltrombopag, anti-thymocyte globulin, and eculizumab; fundamental studies of parvovirus B19, including laboratory assays, a candidate vaccine, and discovery of the cellular receptor and genetic resistance; telomere biology disorders in adults, and the first description of TERT gene mutations in humans; pioneering application of single-cell technologies, RNA and DNA, to characterize hematologic diseases (aplastic anemia, large granular lymphocytosis, DADA2, GATA2, and malignant aneuploidy); and characterization of somatic mutation “benign” diseases. He has published almost 600 research articles, including more than two dozen papers in the New England Journal of Medicine, as well as many textbook chapters and monographs; per Google Scholar, his work has been cited more than 85,000 times, and his h-index is 157.
Dr. Young has been elected to the American Society for Clinical Investigation and the American Association of Physicians and is a Master of the American College of Physicians. He has been honored by the American Society of Hematology, ACP, many national hematology societies, and both the American and Vietnamese governments. In the 1990s, Dr. Young established a formal teaching program in Vietnam, which sponsored annual visits of American experts to that country and training of Vietnamese physicians at NIH and elsewhere in the United States. He has been a plenary lecturer at dozens of national congresses.
Dr. Young is renowned as a mentor; comments from trainees frequently cite their experiences as “transformative.” His students now head their own departments in the United States, Europe, Asia, and South America. He has been an American Society of Hematology Global Mentor for trainees from Brazil, Myanmar, India, and the Netherlands. He co-founded and led for a decade the innovative and successful trans-NIH Center for Human Immunology.
Dr. Young has extensive experience as an editor and reviewer, as well as an author. His economic analysis of the Winner’s Curse in PLoS Medicine has been influential in the current crisis in medical publishing. As a Visiting Fellow at New College, Oxford, his collaboration with a philosopher has resulted in a novel and profound language perspective on scientific communication.
Speaking At
